Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders. Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com. Further information: www.asceneuron.com
View Top Employees from Asceneuron SAWebsite | http://www.asceneuron.com/ |
Revenue | $6 million |
Employees | 18 (13 on RocketReach) |
Founded | 2012 |
Address | Epfl Innovation Park Bâtiment B, Lausanne CH-1015, CH |
Phone | +41 21 693 82 42 |
Technologies |
HTML,
PHP,
reCAPTCHA
+8 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Biotechnology, Orphan Diseases, Business Services, Science and Engineering, Tauopathies, Health Care, Alzheimer's disease, Therapeutics, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics |
Web Rank | 10 Million |
Keywords | Asceneneuron Hq, Asceneuron Sa, Asceneuron |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 541714 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies |
Looking for a particular Asceneuron SA employee's phone or email?
The Asceneuron SA annual revenue was $6 million in 2024.
Bruno Permanne is the Head biology of Asceneuron SA.
13 people are employed at Asceneuron SA.
The NAICS codes for Asceneuron SA are [541714, 54, 541, 5417, 54171].
The SIC codes for Asceneuron SA are [873, 87].